|Table of Contents|

Predictive value of clinical and pathological features and DCE-MRI in breast cancer recurrence time

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2019 05
Page:
774-779
Research Field:
Publishing date:

Info

Title:
Predictive value of clinical and pathological features and DCE-MRI in breast cancer recurrence time
Author(s):
Niu Wei; Luo Yahong; Yu Tao; Zhang Yi; Peng Tengfei; Ma Xiaowen; Li Puchen
Department of Medical Imaging，China Medical University Cancer Hospital，Liaoning Province Tumor Hospital，Liaoning Shenyang 110042，China.
Keywords:
breast cancer; recurrence time; DCE-MRI; clinicopathological features
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2019.05.015
Abstract:
Objective：To analyze the clinicopathological characteristics，DCE-MRI morphology and quantitative parameters of breast cancer patients for predicting the time of recurrence.Methods：Retrospectively analyzed the data of breast cancer patients who were diagnosed in our hospital from November 2012 to December 2014 by postoperative pathology.All patients had preoperative mammary MRI and were followed up for more than 3 years，fifty-eight patients with recurrence were confirmed by pathology or regular imaging examination.They were compared between clinicopathology and DCE-MRI characteristics in patients with early recurrence(postoperative≤2 years) and late recurrence(postoperative＞2 years).Results：In the analysis of clinicopathologic features，58 patients had the highest recurrence rate of breast cancer within 2 years.The average recurrence time was 23 months(range 5~49 months).The first recurrence and metastasis site was more common in bone.Lymph node metastasis＜4 was more common in the late recurrence group，and ≥4 was more common in the early recurrence group.There was a statistically significant difference between the two groups(P<0.05).Positive HER-2 was more common in early recurrence group，and negative was more common in late recurrence group.There was a statistically significant difference between the two groups (P<0.05).In the DCE-MRI characteristics，there was a difference in Vpmax，MaxConcmean，AUCmean，MaxSlopemean between the early recurrence group and the late recurrence group(P<0.05).Conclusion：Number of lymph node metastasis，immunohistochemical phenotype and DCE-MRI dynamic parameters of breast cancer patients have a certain value in predicting the recurrence time of breast cancer patients.

References:

［1］Ferlay J，Soerjomataram I，Dikshit R，et al.Cancer incidence and mortality worldwide：Sources，methods and major patterns in GLOBOCAN 2012［J］.Int J Cancer，2015，136(5)：E359.
［2］Fidler MM，Gupta S，Soerjomataram I，et al.Cancer incidence and mortality among young adults aged 20~39 years worldwide in 2012：A population-based study［J］.Lancet Oncology，2017，18(12)：1579-1589.
［3］Mj VDS，Poortmans PM，Scheepers SW，et al.Prognosis following local recurrence after breast conserving treatment in young women with early breast cancer［J］.Eur J Surg Oncol，2013，39(8)：892-898.
［4］Largillier R，Ferrero JM，Doyen J，et al.Prognostic factors in 1 038 women with metastatic breast cancer［J］.Ann of Oncol，2008，19(12)：2012-2019.
［5］Xia Haiping，Gao Shaorong.Analysis on risk factors of recurrence and metastasis of breast cancer after breast-conserving surgery for patients with breast cancer［J］.Biome Res India，2017，28(16)：7047-7050.
［6］Zhang LL，Ma L，Geng CZ，et al.Correlation between extranodal invasion in axillary lymph node metastasis and prognosis of breast cancer patients［J］.Chinese Journal of Pathology，2017，46(8)：525.
［7］Nishimura R，Osako T，Nishiyama Y，et al.Evaluation of factors related to late recurrence-later than 10 years after the initial treatment-in primary breast cancer［J］.Oncology，2013，85(2)：100.
［8］Choi EJ，Choi HM，Choi SA，et al.Dynamic contrast-enhanced breast magnetic resonance imaging for the prediction of early and late recurrences in breast cancer［J］.Medicine，2016，95(48)：e5330.
［9］Van BV，Van CB，Brouckaert O，et al.Qualitative assessment of the progesterone receptor and HER2 improves the nottingham prognostic index up to 5 years after breast cancer diagnosis［J］.J Clin Oncol，2010，28(27)：4129-4134.
［10］Beata B，Joanna N，Marek Z.Microvessel density and status of p53 protein as potential prognostic factors for adjuvant anthracycline chemotherapy in retrospective analysis of early breast cancer patients group［J］.Pathol Oncol Res Por，2012，18(4)：949-960.
［11］Ahn SG，Lee HM，Cho SH，et al.The difference in prognostic factors between early recurrence and late recurrence in estrogen receptor-positive breast cancer：Nodal stage differently impacts early and late recurrence［J］.PLoS One，2013，8(5)：e63510.
［12］Liu Qi，Guo Xiaolong，Zuo Wenshu，et al.Correlation between recurrence and metastasis of breast cancer and clinicopathological factors［J］.Chinese J Cancer Prevention and Treatment，2014，21(7)：522-527.［刘琪，郭晓龙，左文述，等.乳腺癌术后复发转移间隔与临床病理因素相关性分析［J］.中华肿瘤防治杂志，2014，21(7)：522-527.］
［13］Zheng Zhaoxiang，Wu Mingxia，Zhou Dake，et al.Expression of HER-2 in breast cancer and its relationship with metastasis and prognosis［J］.Chinese J Modern Surg，2007，3(19)：1586-1588.［郑兆祥，武明霞，周大可，等.HER-2在乳腺癌中的表达与转移和预后的关系［J］.中华现代外科学杂志，2007，3(19)：1586-1588.］
［14］Makkat S，Luypaert R，Stadnik T，et al.Deconvolution-based dynamic contrast-enhanced MRI imaging of breast tumors：Correlation of tumor blood flow with human epidermal growth factor receptor 2 status and clinicopathologic findings—preliminary results［J］.Radiology，2009，249(2)：471-482.
［15］Schmitz AM，Loo CE，Wesseling J，et al.Association between rim enhancement of breast cancer on dynamic contrast-enhanced MRI and patient outcome：Impact of subtype［J］.Breast Cancer Res & Trea，2014，148(3)：541-551.
［16］Geng Fengyong，Zheng Yinghui，Wang Yonghui，et al.Clinical observation of postoperative prescription in the prevention of recurrence and metastasis of positive HER2 breast cancer［J］.Modern Oncology，2017，25(6)：908-911.［耿凤勇，郑颖慧，王永辉，等.中药方剂(乳癌术后方）治疗术后HER-2阳性型乳腺癌90例临床观察［J］.现代肿瘤医学，2017，25(6)：908-911.］
［17］Zhu Huiyan，Pei Liqun，Xu Ping，et al.Correlation between DCE-MRI imaging and expression of VEGF and Her-2 in breast cancer［J］.Chinese Journal of CT and MRI，2017，15(06)：72-75.［朱辉严，谌力群，许平，等.乳腺癌DCE-MRI影像表现与VEGF、Her-2表达水平的关系研究［J］.中国CT和MRI杂志，2017，15(06)：72-75.］
［18］Han M，Kim TH，Kang DK，et al.Prognostic role of MRI enhancement features in patients with breast cancer：Value of adjacent vessel sign and increased ipsilateral whole-breast vascularity［J］.Ajr Am J Roentgenol，2012，199(4)：921.
［19］Tan Ru.Correlation analysis of dynamic contrast-enhanced magnetic resonance angiography and prognostic factors in breast cancer［D］.Shandong：Shandong University，2015.［谭茹.动态增强磁共振血管成像与乳腺癌预后因素的相关性分析［D］.山东：山东大学，2015.］

Memo

Memo:
国家公益性行业科研专项基金（编号：201402020）
Last Update: 2019-02-01